Inhibition of IL-12 Production by Thalidomide

Journal of Immunology

Volumn 159, Issue 10, 1997, Pages 5157-5161

  Moller, David R ^a   Wysocka, Maria ^c   Greenlee, Brian M ^a   Ma, Xiaojing ^c   Wahl, Larry ^d   Flockhart, David A ^e   Trinchieri, Giorgio ^c   Karp, Christopher L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c WISTAR INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 12; MESSENGER RNA; MONOCLONAL ANTIBODY; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONOCYTE; MONONUCLEAR CELL;

ANTIBODIES, MONOCLONAL; CELLS, CULTURED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOMETHACIN; INTERLEUKIN-10; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MONOCYTES; RNA, MESSENGER; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031573214     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sheskin, J. 1965. Thalidomide in the treatment of lepra reaction. Clin. Pharmcol. Ther. 6:303.
2. Vogelsang, G. B., E. R. Farmer, A. D. Hess, V. Altamonte, W. E. Beschorner, D. A. Jabs, R. L. Corio, L. S. Levin, O. M. Colvin, J. R. Wingard, and G. W. Santos. 1992. Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326:1055.
3. Carlesimo, M., S. Giustini, A. Rossi, P. Bonaccorsi, and S. Calvieri. 1995. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J. Am. Acad. Dermatol. 32:866.
4. Gutierrez-Rodriguez, O., P. Starusta-Bacal, and O. Gutierrez-Montes. 1989. Treatment of refractory rheumatoid arthritis - the thalidomide story. J. Rheumatol. 16:158.
5. Sampaio, E. P., E. N. Sarno, R. Galilly, S. A. Cohn, and G. Kaplan. 1991. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med. 173:699.
6. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
7. Trinchieri, G., and P. Scott. 1994. The role of interleukin-12 in the immune response, disease and therapy. Immunol. Today. 15:460.
8. Trembleau, S., T. Germann, M. K. Gately, and L. Adorini. 1995. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today 16:363.
9. Germann, T., J. Szeliga, H. Hess, S. Storkel, F. J. Podlaski, M. K. Gately, E. Schmitt, and E. Rude. 1995. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc. Natl. Acad. Sci. USA 92:4823.
10. Williamson, E., P. Garside, J. A. Bradley, and A. M. Mowat. 1996. IL-12 is a central mediator of acute graft-versus-host disease in mice. J. Immunol. 157:689.
11. Moller, D. R., J. D. Forman, M. C. Liu, P. W. Noble, B. M. Greenlee, P. Vyas, D. A. Holden, J. M. Forrester, A. Lazarus, M. Wysocka, G. Trinchieri, and C. Karp. 1996. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J. Immunol. 156:4952.
12. Modlin, R. E. 1994. Th1-Th2 paradigm: insights from leprosy. J. Invest. Dermatol. 102:828.
13. Rea, T. H., and R. L. Modlin. 1992. Leprosy. In Clinical Dermatology, Vol. 3. D. J. Demis, ed. Harper and Row, Inc., Hagerstown, p. 1.
14. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 94:599.
15. Chen, T-L., G. Vogelsang, B. G. Petty, R. B. Brundrett, D. A. Noe, G. W. Santos, and O. M. Colvin. 1989. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab. Dispos. 17:402.
16. Boughton, B. J., T. M. T. Sheehan, J. Wood, D. O'Brien, M. Butler, A. Simpson, and K. A. Hale. 1995. High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Ann. Clin. Biochem. 32:79.
17. Wahl, L. M., I. M. Katonia, R. L. Wilder, C. C. Winter, B. Haraoui, I. Scher, and S. M. Wahl. 1984. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). Cell Immunol. 85:373.
18. D'Andrea A., M. Renharaju, N. M. Valiante, J. Chehimi, M. Kubin, M. Aste, S. H. Chan, M. Kobayashi, D. Young, E. Nickbarg, R. Chizzonite, S. F. Wolf, and G. Trinchieri. 1992. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med. 176:1387.
19. D'Andrea, A., X. Ma, M. Aste-Amezage, C. Paganin, and G. Trinchieri. 1995. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor α production. J. Exp. Med. 181:537.
20. McHugh, S. M., I. R. Rifkin, J. Deighton, A. B. Wilson, P. J. Lachman, C. M. Lockwood, and P. W. Ewan. 1995. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. 99:160.
21. Kubin, M., J. M. Chow, and G. Trinchieri. 1994. Differential regulation of interleukin-12 (IL-12), tumor necrosis factor α, and IL1β production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 83:1847.
22. van der Pouw Kraan, T. C., L. C. Boeije, R. J. Smeenk, J. Wijdenes, and L. A. Aarden. 1995. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:775.
23. Moreira, A., E. P. Sampaio, A. Zmuidzinas, P. Frindt, K. A. Smith, and G. Kaplan. 1993. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177:1675.
24. Sampaio, E. P., G. Kaplan, A. Miranda, J. A. Nery, C. P. Miguel, S. M. Viana, and E. N. Sarno. 1993. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168:408.
25. Seder, R. A., B. L. Kelsall, and D. Jankovic. 1996. Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J. Immunol. 157:2745.
26. Maini, R. N., M. J. Elliott, F. M. Brennan, and M. Feldmann. 1995. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin. Exp. Immunol. 101:207.
27. Holler E., H. J. Kolb, J. Mittermuller, M. Kaul, G. Ledderose, T. Duell, B. Seeber, M. Schleuning, R. Hintermeier-Knabe, B. Ertl, J. Kempeni, and W. Wilmanns. 1995. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86:890.
28. Makonkawkeyoon, S., R. N. R. Limson-Pobre, A. L. Moreira, V. Schauf, and G. Kaplan. 1993. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:5974.
29. Chehimi J., S. Starr, I. Frank, A. D'Andrea, X. Ma, R. R. MacGregor, J. Sennelier, and G. Trinchieri. 1994. Impaired interleukin-12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 179:1361.
30. Clerici, M. C. 1993. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262:1721.